Welcome to our dedicated page for POMDOCTOR SEC filings (Ticker: POM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to host U.S. regulatory filings for POMDOCTOR LIMITED (NASDAQ: POM), an online medical services platform for chronic diseases in China whose American Depositary Shares trade on the Nasdaq Global Market under the symbol POM. While specific SEC filings are not listed in the available data, the company has referenced a registration statement on Form F-1 in connection with its initial public offering of ADSs.
For a foreign private issuer such as POMDOCTOR LIMITED, key SEC filings typically include a registration statement like Form F-1 for an initial public offering, followed by annual reports and other submissions that describe the company’s business, risk factors, and financial statements. These filings are relevant for understanding Pomdoctor’s Internet hospital and pharmaceutical supply chain segments, its focus on chronic disease management and pharmaceutical services, and the structure of its American Depositary Shares.
On Stock Titan, Pomdoctor’s filings page is designed to surface these documents as they become available from the EDGAR system and to pair them with AI-generated explanations. When filings such as an annual report or other disclosure documents are available, AI summaries can help clarify segment information related to the Internet hospital and pharmaceutical supply chain, as well as the company’s stated mission to provide prevention and treatment solutions for chronic diseases in China.
Users interested in POM can use this page to access Pomdoctor’s regulatory history in one place, track updates related to its ADS offering, and review how the company describes its operations, risk profile, and financial reporting in official SEC documents, once those are accessible.
POMDOCTOR LIMITED plans a major change to its American Depositary Share structure. Each ADS will shift from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares, effectively a one-for-eighteen reverse ADS split for ADS holders.
The company expects the ADS ratio change to take effect on or about June 22, 2026, after a post-effective amendment to its Form F-6 becomes effective. Existing ADSs held through DRS and DTC will be automatically exchanged, with eighteen current ADSs consolidated into one new ADS.
Fractional new ADS entitlements will be aggregated and sold by Citibank, N.A., the depositary bank, with net cash proceeds distributed to ADS holders. The company states that the change will not affect the underlying Class A ordinary shares, which will not be issued or cancelled, and the ADSs will continue trading on Nasdaq under the ticker “POM.”
Pomdoctor Limited reported strong top-line growth but sharply higher losses for fiscal 2025. Net revenues rose 16.7% to RMB399.9 million (US$57.2 million), driven mainly by expansion of its Internet hospital business and online pharmacy sales. Gross profit increased 9.6% to RMB52.3 million (US$7.5 million), with gross margin dipping slightly to 13.1% from 13.9%.
Operating expenses more than doubled to RMB170.9 million (US$24.4 million) as the company boosted R&D by 328.5% and incurred significant non-recurring IPO-related costs. Net loss widened to RMB130.9 million (US$18.7 million) from RMB37.4 million, and net cash used in operating activities jumped to RMB148.5 million (US$21.2 million). Pomdoctor completed a Nasdaq IPO in October 2025, raising gross proceeds of US$23.0 million, which helped lift cash and cash equivalents to RMB9.6 million (US$1.4 million) at year-end.
PomDoctor Limited filed its 2025 Form 20-F reporting rapid revenue growth but deepening losses and going-concern risk. Net revenues reached RMB399.9 million for 2025, up from RMB342.6 million in 2024 and RMB304.9 million in 2023, driven by its China-based digital healthcare platform.
The company recorded a 2025 net loss of RMB130.9 million (US$18.7 million) and negative operating cash flow of RMB148.5 million, with net current liabilities of RMB113.2 million as of December 31, 2025. Its auditor expressed substantial doubt about PomDoctor’s ability to continue as a going concern.
PomDoctor operates as a Cayman holding company relying on a variable interest entity structure in China, exposing investors to PRC regulatory, foreign exchange, data security and HFCAA-related risks that could affect its ADS listing and the value of its securities.
POMDOCTOR Ltd disclosed an initial ownership report for director Bao Wenqing. The filing identifies Bao as a director of the company but shows no reported stock transactions or derivative positions, and the transaction summary indicates zero buys, sells, exercises, gifts, or other movements.
POMDOCTOR LIMITED has changed its independent registered public accounting firm. On April 20, 2026, the company dismissed Marcum Asia CPAs LLP and appointed HYYH CPA LLC to audit its consolidated financial statements for the year ended December 31, 2025.
The company states there were no disagreements with Marcum on accounting principles, financial statement disclosure, or audit scope for the years ended December 31, 2023 and 2024, and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting. These weaknesses include insufficient U.S. GAAP/SEC expertise, incomplete financial reporting policies and procedures, and weaknesses in system access security and change management.
POMDOCTOR Ltd director Li Daxue Donnelly has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The excerpt shows no reported transactions or derivative positions, indicating this filing is primarily an administrative disclosure of insider status rather than trading activity.
POMDOCTOR LIMITED reported that Dexiang Wei resigned as Vice President, with the resignation dated March 31, 2026 and effective April 1, 2026. The company states that his departure was not due to any disagreement with the Board on operations, policies, or practices, and there are no related matters requiring shareholder attention.
POMDOCTOR Ltd director Jing Yuanyuan Crystal filed an initial Form 3, which is a mandatory disclosure of insider status. The filing shows no reported transactions or share holdings at this time, serving only to register her as a reporting insider of the company.
POMDOCTOR Ltd filed an initial ownership report showing that Chief Financial Officer Xu Li jinfuhua has an indirect interest in 800,000 Class B ordinary shares held by HEALTHYTEN LIMITED. These Class B shares carry twenty votes per share, compared with one vote for each Class A ordinary share.
Each Class B ordinary share is convertible into one Class A ordinary share at any time by its holder, while Class A ordinary shares are not convertible into Class B ordinary shares. HEALTHYTEN LIMITED is wholly owned by Li Xu, who has granted an irrevocable voting proxy over all Class B shares beneficially owned by HEALTHYTEN LIMITED to Zhenyang Shi.
POMDOCTOR Ltd officer Wei Dexiang filed an initial Form 3 as a reporting person for the company’s securities. Wei is identified as a Vice President, and this filing establishes their insider status and disclosure obligations. No share transactions or holdings are reported in this Form 3 submission.